Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by NLS Pharmaceutics AG

NLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property
Tickers NLSP NLSPW
NLS Pharmaceutics Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Announces Receipt of NASDAQ Minimum Bid Price Notification
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Appoints Chad C. Hellmann as Chief Financial Officer
From NLS Pharmaceutics AG
Via AccessWire
Topics Bankruptcy Initial Public Offering
Tickers NLSP NLSPW
NLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience(R) for the Treatment of Narcolepsy
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Achieves 90% Enrollment Milestone in Quilience(R) Phase 2a Clinical Trial for Patients with Narcolepsy
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property
Tickers NLSP NLSPW
NLS Pharmaceutics Ltd. Announces Closing of US$4.4 Million Registered Direct Offering
From NLS Pharmaceutics AG
Via AccessWire
Topics Regulatory Compliance
Tickers NLSP NLSPW
NLS Pharmaceutics to Participate in the B. Riley Annual Neuro & Ophthalmology Investor Conference
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Retains LifeSci Partners As Financial Advisor To Evaluate Strategic Partnering Initiatives
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Announces Early Access Program (EAP) Allowing Patients with Idiopathic Hypersomnia to Receive Treatment with Mazindol ER
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics to Participate in Maxim Group 2022 Virtual Growth Conference
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Announces Positive Interim Top-Line Data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics to Participate in the SACHS 15th Annual European Life Sciences Virtual CEO Forum and a Fireside Chat with Maxim Analyst in March
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics to Participate in 2022 BIO CEO & Investor Conference
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics to Present Interim Top-Line Data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy at the World Sleep Congress in March 2022
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Invites Patients, Caregivers and Other Interested Parties to Attend International Narcolepsy Webinar
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Announces Patent Issuance in the United States for its Mazindol Extended-Release Formulation
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property
Tickers NLSP NLSPW
NLS Pharmaceutics Announces Preclinical Results Confirming the Potential Benefit and Safety Profile of NLS-4 for Circadian Rhythm Dysregulation and Chronic Fatigue Syndrome in Long-Covid Model
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers NLSP NLSPW
NLS Pharmaceutics CEO Issues Letter to Shareholders
From NLS Pharmaceutics AG
Via AccessWire
Topics Initial Public Offering Intellectual Property Regulatory Compliance
Tickers NLSP NLSPW
NLS Pharmaceutics Announces Preclinical Data Demonstrating the Potential of NLS-4 (Lauflumide) to Treat Chronic Fatigue Associated With Long-COVID
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property Product Recall Regulatory Compliance
Tickers NLSP NLSPW
NLS Pharmaceutics to Participate in The Micro Cap Rodeo Fall Harvest Conference: Best Ideas from the Buy-side
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers NLSP NLSPW
NLS Pharmaceutics to Participate in the Benzinga Healthcare Small Cap Conference
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Initiates Phase 2 Trial for Quilience in Narcolepsy and Announces First Patient Enrolled
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers NLSP NLSPW
NLS Pharmaceutics to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Application Covering its Proprietary Mazindol Formulation
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers NLSP NLSPW
NLS Pharmaceutics to Participate in the Canaccord Genuity 41st Annual Growth Conference
From NLS Pharmaceutics AG
Via AccessWire
Tickers NLSP NLSPW
NLS Pharmaceutics Announces the Appointment of Eric Konofal, M.D., Ph.D. as Chief Scientific Officer
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers NLSP NLSPW
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.